# PUBLIC SUMMARY DOCUMENT

**Product:** Omnigon Eakin Dot One Piece Drainable Convex Baseplate

**Applicant:** Omnigon

**Date of SPAP Meeting:** 20 April 2021

## Proposed Listing on the Stoma Appliance Scheme

The applicant, Omnigon sought listing of the Omnigon Eakin Dot One Piece Drainable Convex Baseplate in subgroup 2(b) of the Stoma Appliance Scheme (SAS) Schedule. The proposed product, including 13 variants, was proposed for listing at a unit price of $6.373, with a maximum monthly quantity of 30 units.

## Comparator

The applicant nominated the Omnigon Pelican (SAS code 9894R) as the comparator. The product is currently listed in subgroup 2(b) of the SAS Schedule at the unit price of $6.373, with a maximum monthly quantity of 30 units. The Stoma Product Assessment Panel (SPAP) accepted this product as an acceptable comparator

## Background

This was the SPAP’s first consideration of this product.

## Clinical Place for the Product

The proposed product is an alternative for users requiring one piece drainable convex baseplate.

## SPAP Comment

### Clinical Analysis

The Panel noted the proposed product is considered to be equivalent to products currently available at the benchmark price in subgroup 2(b). The Panel also noted that no comparative data was provided.

### Economic Analysis

Not undertaken.

### Financial Analysis

Listing of this product is recommended on a cost-minimisation basis compared to products currently listed in subgroup 2(b) of the SAS Schedule. It is therefore unlikely that there would be any budgetary impact for the SAS as a consequence of listing this product.

## SPAP Recommendation

The SPAP recommended that the Omnigon Eakin Dot One Piece Drainable Convex Baseplate, including 13 variants be listed in subgroup 2(b) of the SAS Schedule at the unit price of $6.373, with a maximum monthly quantity of 30 units.

## Context for Decision

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. A SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the SPAP following a decision not to recommend listing or changes to a listing. The SPAP is an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.

## Applicant’s Comment

Omnigon agrees with the SPAP’s recommendation.